ReviewDrugs1994
Quinolone antibacterials. An update of their pharmacology and therapeutic use.
Review in Drugs, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 153 citations in OpenAlex.
- Some pharmacokinetic parameters of pefloxacin in lactating goats.Veterinary research communications · 2002Trial
- Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.Antimicrobial agents and chemotherapy · 1998Trial
- Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.Antimicrobial agents and chemotherapy · 1997Trial
- Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones.PharmacoEconomics · 1997Trial
- A multi-metric evaluation of a sustainable capillary electrophoresis method for simultaneous therapeutic drug monitoring of Nilotinib and Ofloxacin in oncology clinics.Scientific reports · 2026Article
- Occurrence and Dietary Exposure Assessment of Quinolone Antibiotics in Animal-Derived Foods and Associated Health Risks Among Different Population Groups in Guangzhou, China.Foods (Basel, Switzerland) · 2026Article
- Determination of levofloxacin, norfloxacin, and moxifloxacin in pharmaceutical dosage form or individually using derivative UV spectrophotometry.BMC chemistry · 2024Article
- A New Drug Safety Signal Detection and Triage System Integrating Sequence Symmetry Analysis and Tree-Based Scan Statistics with Longitudinal Data.Clinical epidemiology · 2023Article
- Stoichiometry-Selective Antagonism of α4β2 Nicotinic Acetylcholine Receptors by Fluoroquinolone Antibiotics.ACS chemical neuroscience · 2022Article
- An Updated Review on the Synthesis and Antibacterial Activity of Molecular Hybrids and Conjugates Bearing Imidazole Moiety.Molecules (Basel, Switzerland) · 2020Review
- Currently Available Radiopharmaceuticals for Imaging Infection and the Holy Grail.Seminars in nuclear medicine · 2018Review
- Synthesis and characterization of N-Mannich based prodrugs of ciprofloxacin and norfloxacin:Journal of advanced research · 2017Article
- Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries.Frontiers in pharmacology · 2017Article
- Sparfloxacin-associated corneal epithelial toxicity.BMJ case reports · 2014Article
- Poly(2-hydroxyethyl methacrylate) wound dressing containing ciprofloxacin and its drug release studies.Journal of materials science. Materials in medicine · 2005Article
- Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1998Article
- Influence of renal failure on ciprofloxacin pharmacokinetics in rats.Antimicrobial agents and chemotherapy · 1998Article
- In vitro activities of new quinolones against Helicobacter pylori.Antimicrobial agents and chemotherapy · 1997Article
- Characterization of DNA topoisomerase activity in two strains of Mycoplasma fermentans and in Mycoplasma pirum.Journal of bacteriology · 1997Article
- In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections.Antimicrobial agents and chemotherapy · 1997Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quinolones are a class of antibiotics structurally related to nalidixic acid. They exhibit bactericidal activity primarily by inhibiting bacterial DNA gyrase. The early quinolones had a limited spectrum of activity, low potency, high frequency of spontaneous bacterial resistance, low serum drug concentrations and short half-lives, which virtually restricted their use to urinary tract infection. The new fluorinated quinolones differ from their predecessors in their broad antibacterial spectrum, including both Gram-negative and Gram-positive aerobic, and facultative anaerobic bacteria as well as many Mycobacterium spp., Chlamydia spp., Legionella spp. and Mycoplasma spp., in addition to many strains of bacteria that are multiresistant to beta-lactam antibiotics and aminoglycosides. They also exhibit high potency, a low incidence of resistance, high oral bioavailability, extensive tissue penetration, low protein binding and long elimination half-lives. They are generally well tolerated apart from some gastrointestinal disturbance and rashes, including photosensitive eruptions and a propensity to cause central nervous system excitation. Clinically important interactions include those with antacids, theophylline, fenbufen and warfarin. Potential toxic effects include cartilage damage, ocular toxicity, teratogenicity and impairment of spermatogenesis. The role of fluoroquinolones continues to widen, encompassing infections of the urinary tract, respiratory tract, skin and soft tissues, bone and joints, infections in immunocompromised patients, sexually transmitted diseases, infectious diarrhoea, gynaecological infections and surgical prophylaxis. The convenience of oral therapy is an added advantage of the new fluoroquinolones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.